The Abbott Esprit BTK everolimus-eluting biosorbable scaffold system for below the knee peripheral artery disease on display at TCT 2024. Photo by Dave Fornell
It's another big victory for Abbott's bioresorbable stent for BTK PAD.
When Taylor Swift speaks, the world listens. And when she recently appeared on a podcast for the very first time, she shared the story of how a nuclear stress test saved her father's life.
"We're constantly trying to keep our fingers on the pulse of what's happening in the real world," explained Joan Michaels, RN, director of the STS/ACC TVT Registry. "This is not a trial; this is real-world experience."
The Class I recall includes more than 26,000 vascular stents from Boston Scientific. These devices have been linked to a risk of potential resistance when the stent delivery system is being withdrawn.
Boston Scientific's Farapulse PFA system. Image courtesy of Boston Scientific.
“We believe that any iatrogenic complication should be reported,” the study's authors wrote. “No patient expects to be discharged from hospital with a new diaphragmatic deficit without being informed."
Cardiology faces one of its most challenging decades ahead, with mounting pressures from workforce shortages, an aging population and declining reimbursements. To remain sustainable, practices are forced to rethink how care is delivered from the ground up.
"This important study will evaluate the potential benefits of the AGENT DCB for patients with certain anatomical features in de novo coronary lesions, where the avoidance of stents is preferable to help circumvent potential complications,” said Janar Sathananthan, MD, chief medical officer, interventional cardiology therapies, Boston Scientific.
"Eko is transforming how we detect cardiovascular disease—making cutting-edge, AI-powered tools accessible to frontline providers," said former U.S. Surgeon General Jerome Adams, MD.
